share_log
Benzinga ·  05/02 07:45

Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint

Organogenesis宣布其评估ReNU安全性和有效性的3期随机对照试验达到其主要终点后,该公司股价走高

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发